Literature DB >> 35750941

Bicyclol Attenuates Obesity-Induced Cardiomyopathy via Inhibiting NF-κB and MAPK Signaling Pathways.

Yanghao Chen1,2, Wante Lin1,2, Lingfeng Zhong1, Zimin Fang1,2, Bozhi Ye1,2, Zhe Wang3, Nipon Chattipakorn4, Weijian Huang5, Guang Liang6,7,8, Gaojun Wu9.   

Abstract

PURPOSE: Schisandra is a well-known traditional Chinese medicine in East Asia. As a traditional Chinese medicine derivative with Schisandra chinensis as raw material, bicyclol is well known for its significant anti-inflammatory effect. Chronic inflammation plays a significant part in obesity-induced cardiomyopathy. Our purpose was to explore the effect and mechanism of bicyclol on obesity-induced cardiomyopathy.
METHODS: Mice fed with a high-fat diet (HFD) and cardiomyocytes stimulated by palmitic acid (PA) were used as models of obesity-related cardiomyopathy in vivo and in vitro, respectively. The therapeutic effect of bicyclol on pathological changes such as myocardial hypertrophy and fibrosis was evaluated by staining cardiac tissue sections. PCR was used to detect inflammatory factors in H9c2 cells and animal heart tissue after bicyclol treatment. Then, we used western blotting to detect the expression levels of the myocardial hypertrophy related protein, myocardial fibrosis related protein, NF-κB and MAPK pathways.
RESULTS: Our results indicated that bicyclol treatment significantly alleviates HFD-induced myocardial inflammation, fibrosis, and hypertrophy by inhibiting the MAPK and NF-κB pathways. Similar to animal level results, bicyclol could significantly inhibit PA-induced inflammation and prevent NF-κB and MAPK pathways from being activated.
CONCLUSION: Our results showed that bicyclol has potential as a drug to treat obesity-induced cardiomyopathy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  MAPK; NF-κB; Obesity-induced cardiomyopathy; bicyclol

Year:  2022        PMID: 35750941     DOI: 10.1007/s10557-022-07356-6

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  2 in total

Review 1.  Progress of Research into Novel Drugs and Potential Drug Targets against Porcine Pseudorabies Virus.

Authors:  Mo Zhou; Muhammad Abid; Shinuo Cao; Shanyuan Zhu
Journal:  Viruses       Date:  2022-08-11       Impact factor: 5.818

2.  Protective Effect of Shengmaiyin in Myocardial Hypertrophy-Induced Rats: A Genomic Analysis by 16S rDNA.

Authors:  Sitong Ming; Mo Kan; Liu Liu; Zhuang Zhang; Xiaoran Liu; Yaxin Liu; Zhen Li; Yanhong Zhang; Qihang Pang; Jianan Lin; Hui Li; Qing Yang; Xin Sui; Xiaobo Qu; Na Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-07       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.